Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey

References

• Breccia M, Abruzzese E, Annunziata M, et al. Clinical and psychological factors to consider in achieving Treatment-Free remission in patients with chronic myeloid leukemia. Front Oncol. 2021;11:631570.
   PubMed Web of Science ®Google Scholar
• Garcia-Horton A, Lipton JH. Treatment outcomes in chronic myeloid leukemia: does one size fit all? J Natl Compr Canc Netw. 2020;18(10):1421–1428.
   PubMed Web of Science ®Google Scholar
• Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Loiseau C, Delord M, et al. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv. 2020;4(13):3034–3040.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Bonifazi F, Soverini S, et al. Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia. Leukemia. 2022;36(5):1227–1236.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver R, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Deininger M, Shah N, Altman J, et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(10):1385–1415.
   PubMed Web of Science ®Google Scholar
• Kang D, Bae K, Kim H, et al. Changes in working status after cancer diagnosis and socio-demographic, clinical, work-related, and psychological factors associated with it. BMC Cancer. 2022;22(1):917.
   PubMed Web of Science ®Google Scholar
• Ono TJC. Which tyrosine kinase inhibitors should be selected as the First-Line treatment for chronic myelogenous leukemia in chronic phase? Cancers. 2021;13(20):5116.
   PubMed Web of Science ®Google Scholar
• García-Gutiérrez V, Breccia M, Jabbour E, et al. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15(1):90. oncology
   PubMed Web of Science ®Google Scholar
• Garcia-Gutierrez V, Hernandez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603.
   PubMed Web of Science ®Google Scholar
• Saglio G, Jabbour EJL. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma. 2018;59(7):1523–1538.
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Cross N, Ali S, et al. Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. Br J Haematol. 2021;192(1):62–74.
   PubMed Web of Science ®Google Scholar
• Yu L, Qin YZ, Jiang Q. Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center. Chin J Hematol. 2017;38(9):754–760.
   Google Scholar
• Atallah E, Sadek I, Maegawa R, et al. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. Leuk Lymphoma. 2021;62(7):1730–1739.
   PubMed Web of Science ®Google Scholar
• Keating N, Brooks G, Landrum M, et al. The oncology care model and adherence to oral cancer drugs: a difference-in-Differences analysis. J Natl Cancer Inst. 2022;114(6):871–877.
   PubMedGoogle Scholar
• White H, Salmon M, Albano F, et al. Standardization of molecular monitoring of CML: results and recommendations from the european treatment and outcome study. Leukemia. 2022;36(7):1834–1842.
   PubMed Web of Science ®Google Scholar
• Ector G, Govers T, Westerweel P, et al. The potential health gain and cost savings of improving adherence in chronic myeloid leukemia. Leuk Lymphoma. 2019;60(6):1485–1492. lymphoma
   PubMed Web of Science ®Google Scholar
• Yamamoto C, Nakashima H, Ikeda T, et al. Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation. Blood Adv. 2019;3(21):3266–3277.
   PubMed Web of Science ®Google Scholar
• Chinese Society of Hematology CMA. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition). Chin J Hematol. 2020;41(5):353–364.
   Google Scholar
• Abou Dalle I, Kantarjian H, Burger J, et al. Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States. Cancer Med. 2019;8(15):6559–6565.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Paul S, Thakkar J, et al. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol. 2022;9(11):e854–e61.
   PubMed Web of Science ®Google Scholar
• Yu W, Du X, Wang W, et al. Efficacy and safety of generic dasatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: a multicenter prospective study in China. Clin Lymphoma Myeloma Leuk. 2022;22(9):e867–e73.
   PubMed Web of Science ®Google Scholar
• Soverini S, Bavaro L, De Benedittis C, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood. 2020;135(8):534–541.
   PubMed Web of Science ®Google Scholar
• Branford S, Kim D, Apperley J, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019;33(8):1835–1850.
   PubMed Web of Science ®Google Scholar
• Kok C, Yeung D, Lu L, et al. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv. 2019;3(10):1610–1621.
   PubMed Web of Science ®Google Scholar
• Ector G, Verweij L, Hermens R, et al. Filling the gaps of patient information needs and information perception in chronic myeloid leukemia with the patient-physician co-produced web-based platform CMyLife. Patient Educ Couns. 2022;105(3):686–694.
   PubMed Web of Science ®Google Scholar
• Chen H, Wen Y, Zeng Y, et al. Patient-Versus Physician-Perceptions of symptoms, treatment and management in chronic myeloid leukemia. Blood. 2022;140(Supplement 1):10841–10842.
   Google Scholar
• Bower H, Björkholm M, Dickman P, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–2857.
   PubMed Web of Science ®Google Scholar